250 related articles for article (PubMed ID: 29670214)
61. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
62. Posttranslational regulation of neurofibromin content in melanocytes of neurofibromatosis type 1 patients.
Kaufmann D; Bartelt B; Hoffmeyer S; Müller R
Arch Dermatol Res; 1999 Jun; 291(6):312-7. PubMed ID: 10421056
[TBL] [Abstract][Full Text] [Related]
63. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.
Cichowski K; Santiago S; Jardim M; Johnson BW; Jacks T
Genes Dev; 2003 Feb; 17(4):449-54. PubMed ID: 12600938
[TBL] [Abstract][Full Text] [Related]
64. Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism.
Xu Y; Chiamvimonvat N; Vázquez AE; Akunuru S; Ratner N; Yamoah EN
J Neurosci; 2002 Nov; 22(21):9194-202. PubMed ID: 12417644
[TBL] [Abstract][Full Text] [Related]
65. Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.
Sherekar M; Han SW; Ghirlando R; Messing S; Drew M; Rabara D; Waybright T; Juneja P; O'Neill H; Stanley CB; Bhowmik D; Ramanathan A; Subramaniam S; Nissley DV; Gillette W; McCormick F; Esposito D
J Biol Chem; 2020 Jan; 295(4):1105-1119. PubMed ID: 31836666
[TBL] [Abstract][Full Text] [Related]
66. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.
Larizza L; Gervasini C; Natacci F; Riva P
Curr Mol Med; 2009 Jun; 9(5):634-53. PubMed ID: 19601812
[TBL] [Abstract][Full Text] [Related]
67. NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
Pros E; Larriba S; López E; Ravella A; Gili ML; Kruyer H; Valls J; Serra E; Lázaro C
Hum Mutat; 2006 Nov; 27(11):1104-14. PubMed ID: 16937374
[TBL] [Abstract][Full Text] [Related]
68. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Yang FC; Chen S; Robling AG; Yu X; Nebesio TD; Yan J; Morgan T; Li X; Yuan J; Hock J; Ingram DA; Clapp DW
J Clin Invest; 2006 Nov; 116(11):2880-91. PubMed ID: 17053831
[TBL] [Abstract][Full Text] [Related]
69. S100B and neurofibromin immunostaining and X-inactivation patterns of laser-microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas.
Tucker T; Riccardi VM; Brown C; Fee J; Sutcliffe M; Vielkind J; Wechsler J; Wolkenstein P; Friedman JM
J Neurosci Res; 2011 Sep; 89(9):1451-60. PubMed ID: 21674567
[TBL] [Abstract][Full Text] [Related]
70. Neurofibromin interacts with the cytoplasmic Dynein Heavy Chain 1 in melanosomes of human melanocytes.
Arun V; Worrell L; Wiley JC; Kaplan DR; Guha A
FEBS Lett; 2013 May; 587(10):1466-73. PubMed ID: 23583712
[TBL] [Abstract][Full Text] [Related]
71. Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells.
Harigai R; Sakai S; Nobusue H; Hirose C; Sampetrean O; Minami N; Hata Y; Kasama T; Hirose T; Takenouchi T; Kosaki K; Kishi K; Saya H; Arima Y
Sci Rep; 2018 Apr; 8(1):6069. PubMed ID: 29666462
[TBL] [Abstract][Full Text] [Related]
72. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.
Mangoura D; Sun Y; Li C; Singh D; Gutmann DH; Flores A; Ahmed M; Vallianatos G
Oncogene; 2006 Feb; 25(5):735-45. PubMed ID: 16314845
[TBL] [Abstract][Full Text] [Related]
73. Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis.
Bajaj A; Li QF; Zheng Q; Pumiglia K
PLoS One; 2012; 7(11):e49222. PubMed ID: 23145129
[TBL] [Abstract][Full Text] [Related]
74. Neurofibromin is actively transported to the nucleus.
Vandenbroucke I; Van Oostveldt P; Coene E; De Paepe A; Messiaen L
FEBS Lett; 2004 Feb; 560(1-3):98-102. PubMed ID: 14988005
[TBL] [Abstract][Full Text] [Related]
75. Solubility survey of fragments of the neurofibromatosis type 1 protein neurofibromin.
Bonneau F; Lenherr ED; Pena V; Hart DJ; Scheffzek K
Protein Expr Purif; 2009 May; 65(1):30-7. PubMed ID: 19111619
[TBL] [Abstract][Full Text] [Related]
76. Neurofibromatosis: the role of guanosine triphosphatase activating proteins in sensory neuron function.
Hingtgen CM
Sheng Li Xue Bao; 2008 Oct; 60(5):581-3. PubMed ID: 18958364
[TBL] [Abstract][Full Text] [Related]
77. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
Anastasaki C; Orozco P; Gutmann DH
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
[TBL] [Abstract][Full Text] [Related]
78. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
79. Neurofibromatosis type 1 tumour suppressor gene expression is deficient in psoriatic skin in vivo and in vitro: a potential link to increased Ras activity.
Karvonen SL; Koivunen J; Nissinen M; Ylä-Outinen H; Björkstrand AS; Peltonen J
Br J Dermatol; 2004 Feb; 150(2):211-9. PubMed ID: 14996090
[TBL] [Abstract][Full Text] [Related]
80. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
